Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CStone Pharmaceuticals ( (HK:2616) ) is now available.
CStone Pharmaceuticals announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is significant for stakeholders as it outlines the leadership structure and governance, which can impact the company’s strategic direction and operational efficiency.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company incorporated in the Cayman Islands. The company focuses on the development and commercialization of innovative immuno-oncology and precision medicine therapies, primarily targeting the Asian market.
Average Trading Volume: 22,471,424
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.1B
See more data about 2616 stock on TipRanks’ Stock Analysis page.